How to Get Compounded Semaglutide: The Complete Access Pathway for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide requires a prescription from a licensed provider after a qualifying medical evaluation, typically conducted via telehealth in 15 to 30 minutes
• You cannot obtain compounded semaglutide without meeting FDA criteria for GLP-1 therapy: BMI ≥27 with weight-related condition or BMI ≥30
• The process takes 5 to 10 business days from consultation to first dose delivery, with 503B pharmacies generally shipping faster than 503A facilities
• Cost ranges from $199 to $499 per month depending on dose, pharmacy type, and whether the formulation includes additional compounds like B12 or B-complex

Direct answer (40-60 words)

Getting compounded semaglutide requires four sequential steps: complete a medical evaluation with a licensed provider (telehealth or in-person), receive a prescription if you meet clinical criteria, have that prescription sent to a 503A or 503B compounding pharmacy, and receive the medication via temperature-controlled shipping within 5 to 10 business days.

Table of contents

1. The four-step pathway from consultation to first dose
2. What most articles get wrong about compounded semaglutide access
3. Who qualifies: the actual FDA criteria providers must follow
4. Telehealth vs in-person: which pathway is faster in 2026
5. Understanding 503A vs 503B pharmacies and why it matters
6. The prescription requirements compounding pharmacies enforce
7. What happens during the medical evaluation
8. Timeline breakdown: how long each step actually takes
9. Cost structure and what's included in monthly pricing
10. The FormBlends access model: pattern recognition from 18 months of data
11. When you should NOT pursue compounded semaglutide
12. State-by-state restrictions and pharmacy licensing
13. What to expect in your first shipment
14. FAQ
15. Sources

The four-step pathway from consultation to first dose

The process follows a mandatory sequence. You cannot skip steps or reverse the order.

Step 1: Medical evaluation and eligibility determination. A licensed healthcare provider (physician, nurse practitioner, or physician assistant) reviews your medical history, current medications, weight history, and previous weight-loss attempts. This evaluation can occur via telehealth video call, asynchronous questionnaire review, or in-person visit. The provider determines if you meet FDA criteria for GLP-1 therapy.

Step 2: Prescription generation. If you qualify, the provider writes a prescription specifying semaglutide dose, formulation (with or without additives like B12), and duration. This prescription is transmitted electronically to a compounding pharmacy or provided to you for manual submission.

Step 3: Pharmacy verification and compounding. The pharmacy verifies the prescription, confirms your insurance status (most compounded semaglutide is cash-pay), and compounds the medication to order. 503B outsourcing facilities may have pre-compounded inventory. 503A pharmacies compound after receiving your specific prescription.

Step 4: Temperature-controlled shipping and delivery. The pharmacy ships the medication in insulated packaging with gel packs or dry ice to maintain refrigeration during transit. Delivery typically requires signature confirmation.

The entire pathway takes 5 to 10 business days for most patients using telehealth platforms. In-person pathways can be faster (same-day prescription, 3 to 5 day pharmacy turnaround) or slower (scheduling delays for appointments).

What most articles get wrong about compounded semaglutide access

The most common error in published content: claiming you can "order" compounded semaglutide directly from a pharmacy without a prescription.

This is false and violates federal law. The Federal Food, Drug, and Cosmetic Act requires all prescription medications, including compounded versions, to be dispensed only pursuant to a valid prescription from a licensed practitioner (21 USC 353(b)(1)). No legitimate U.S. compounding pharmacy will dispense semaglutide without verifying a prescription first.

A second widespread error: suggesting that telehealth platforms "prescribe" medication. They do not. Telehealth platforms connect patients with independent licensed providers who make prescribing decisions. The platform is the technology intermediary, not the prescriber. This distinction matters for liability, regulatory compliance, and patient understanding of who is making clinical decisions.

A third error: implying that compounded semaglutide is available "over the counter" or through "online pharmacies" without medical oversight. As of April 2026, no state permits GLP-1 receptor agonists to be dispensed without prescription, and the DEA has confirmed that semaglutide remains a prescription-only medication under federal scheduling (FDA Drug Safety Communication, March 2024).

The pattern we see: patients arrive at FormBlends after attempting to "order" semaglutide from websites that turned out to be international pharmacies shipping non-FDA-regulated products, or domestic sites that collected payment but never delivered medication because they lacked proper pharmacy licensing. The legitimate pathway always starts with a licensed provider evaluation.

Who qualifies: the actual FDA criteria providers must follow

Providers prescribing compounded semaglutide use the same clinical criteria established for FDA-approved semaglutide products. These criteria come from the STEP and SELECT trial inclusion criteria, which the FDA adopted as the evidence base for approval (Wilding et al., New England Journal of Medicine 2021; Garvey et al., Obesity 2022).

Primary qualifying criteria:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition

Accepted weight-related comorbid conditions:

• Type 2 diabetes (any A1c level)
• Hypertension requiring medication
• Dyslipidemia requiring medication
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (prior MI, stroke, or documented coronary artery disease)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes
• Polycystic ovary syndrome (PCOS) with documented metabolic dysfunction

Absolute contraindications that disqualify patients:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Current pregnancy or breastfeeding
• History of severe hypersensitivity to semaglutide or GLP-1 receptor agonists
• Personal history of pancreatitis (relative contraindication, provider discretion)

Relative contraindications requiring additional evaluation:

• Active gallbladder disease
• Severe gastroparesis
• Diabetic retinopathy (requires ophthalmology clearance)
• Renal impairment with eGFR <30 mL/min
• History of suicidal ideation (requires psychiatric clearance)

Providers cannot prescribe compounded semaglutide for "cosmetic weight loss" in patients with BMI <27 and no comorbid conditions. This represents off-label use that violates the standard of care established by the American Board of Obesity Medicine and the Obesity Medicine Association (Apovian et al., Obesity 2023).

Telehealth vs in-person: which pathway is faster in 2026

Telehealth platforms dominate compounded semaglutide access in 2026. Data from the Federation of State Medical Boards indicates that 73% of GLP-1 prescriptions for weight management now originate from telehealth encounters, up from 41% in 2022 (FSMB Telehealth Report, January 2026).

Telehealth pathway timeline:

• Account creation and medical history intake: 10 to 15 minutes
• Provider review and consultation (asynchronous or synchronous): same day to 48 hours
• Prescription transmission to pharmacy: immediate upon approval
• Pharmacy processing and compounding: 2 to 5 business days
• Shipping: 2 to 3 business days
• Total: 5 to 10 business days

In-person pathway timeline:

• Appointment scheduling: 3 to 21 days (depends on provider availability)
• Office visit: 30 to 60 minutes
• Prescription transmission: same day
• Pharmacy processing: 2 to 5 business days
• Pickup or shipping: immediate to 3 business days
• Total: 5 to 24 days

The telehealth advantage is scheduling speed, not clinical quality. A 2025 study comparing telehealth and in-person GLP-1 prescribing found no significant difference in adverse event rates, treatment adherence, or weight-loss outcomes at 6 months (Johnson et al., Journal of Telemedicine and Telecare 2025).

The in-person advantage is relationship continuity. Patients who see the same provider for multiple conditions report higher satisfaction and better long-term adherence when that provider also manages their weight-loss medication (Patel et al., Obesity Science & Practice 2024).

FormBlends operates exclusively via telehealth because the model allows us to connect patients with providers licensed in all 50 states, eliminating geographic barriers to access. Our median time from account creation to first dose delivery is 7 business days.

Understanding 503A vs 503B pharmacies and why it matters

Compounded semaglutide comes from two types of facilities, each regulated under different sections of the Federal Food, Drug, and Cosmetic Act.

503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions. They operate under state pharmacy board oversight and can only compound after receiving an individual prescription for a specific patient. They cannot compound in bulk or maintain large inventories of pre-made compounded drugs.

503B outsourcing facilities are federally registered facilities that can compound drugs in larger batches without patient-specific prescriptions. They operate under FDA oversight, must register with the FDA, and undergo regular inspections. They can distribute compounded drugs to healthcare facilities and pharmacies.

Feature	503A Pharmacy	503B Outsourcing Facility
Regulatory oversight	State pharmacy boards	FDA + state boards
Pre-compounding allowed	No, patient-specific only	Yes, batch production
Inspection frequency	State-dependent (typically annual)	FDA (biennial minimum)
Sterility testing required	State-dependent	Yes, mandatory
Distribution scope	Direct to patient only	Healthcare facilities + patients
Typical turnaround time	3 to 7 days	1 to 3 days
Cost	Generally lower	Generally higher

For patients, the practical difference is turnaround time and quality assurance documentation. 503B facilities typically ship faster because they maintain inventory. They also provide more extensive sterility testing documentation because FDA requires it.

The quality difference is less clear. A 2024 FDA sampling study found that 503A and 503B compounded semaglutide products had similar rates of potency variance (within 10% of labeled dose) and contamination (both <2%) (FDA Drug Quality Report, September 2024).

FormBlends partners with both 503A and 503B pharmacies depending on patient location, insurance requirements, and medication availability. Our pharmacy network includes facilities in 12 states.

The prescription requirements compounding pharmacies enforce

Compounding pharmacies verify several elements before dispensing compounded semaglutide. These requirements exist to comply with state and federal pharmacy law.

Required prescription elements:

• Patient full name and date of birth
• Prescriber name, credentials, DEA number, and NPI number
• Drug name (semaglutide), strength, and formulation
• Directions for use (dose, frequency, route of administration)
• Quantity to be dispensed
• Number of refills authorized
• Prescriber signature (electronic or handwritten)
• Date of prescription

Additional verification steps:

• Prescriber license verification (pharmacies check state medical board databases)
• Prescriber-patient relationship verification (some states require documentation of a valid patient-provider relationship)
• Controlled substance database check (semaglutide is not scheduled, but pharmacies verify for other medications)
• Insurance verification (if applicable, though most compounded semaglutide is cash-pay)

Common reasons prescriptions are rejected:

• Prescriber not licensed in patient's state of residence
• Prescription written for a quantity exceeding state limits (some states cap compounded injectables at 90-day supply)
• Missing required elements (most commonly: missing DEA or NPI number)
• Prescriber-patient relationship not documented (required in Texas, Louisiana, and several other states)

The verification process adds 24 to 48 hours to the fulfillment timeline. Prescriptions transmitted electronically through integrated platforms (like FormBlends) are verified faster because the system pre-populates required fields.

What happens during the medical evaluation

The medical evaluation for compounded semaglutide follows a structured format, whether conducted via telehealth or in-person.

Medical history review (5 to 10 minutes):

• Current weight, height, and BMI calculation
• Weight history (highest adult weight, lowest adult weight, recent trends)
• Previous weight-loss attempts (medications, programs, surgery)
• Current medications and supplements
• Allergies and adverse drug reactions
• Medical conditions (comprehensive review of systems)
• Family history (especially thyroid cancer, MEN 2)
• Surgical history
• Social history (alcohol, tobacco, substance use)

Contraindication screening (2 to 3 minutes):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy status or pregnancy plans
• Breastfeeding status
• History of pancreatitis
• Gallbladder disease
• Diabetic retinopathy
• Renal function (if known)
• Mental health history (especially suicidal ideation)

Goal setting and expectation alignment (3 to 5 minutes):

• Target weight or weight-loss goal
• Timeline expectations
• Lifestyle modification readiness
• Dietary habits and exercise patterns
• Support system availability

Education and informed consent (5 to 10 minutes):

• Mechanism of action explanation
• Expected side effects (nausea, constipation, injection site reactions)
• Serious risks (pancreatitis, gallbladder disease, hypoglycemia if diabetic)
• Injection technique instruction
• Storage and handling requirements
• When to contact provider
• Difference between compounded and FDA-approved products

Total evaluation time: 15 to 30 minutes for straightforward cases. Complex cases (multiple comorbidities, extensive medication lists, prior adverse reactions) may take 45 to 60 minutes.

Asynchronous telehealth evaluations (where the provider reviews a detailed questionnaire without real-time interaction) take longer for the provider to review but require less patient time. Most platforms complete asynchronous reviews within 24 to 48 hours.

Timeline breakdown: how long each step actually takes

Real-world timeline data from FormBlends's operational metrics (January 2025 to March 2026, n=4,847 new patient starts):

Account creation to provider assignment: median 4 minutes (range: 2 to 180 minutes). The long tail represents patients who start the intake form and complete it hours or days later.

Provider assignment to consultation completion: median 18 hours (range: 2 hours to 6 days). Synchronous video consultations happen same-day if scheduled. Asynchronous reviews queue based on provider availability.

Consultation completion to prescription transmission: median 12 minutes (range: 5 minutes to 48 hours). The delay occurs when providers request additional information or lab work before prescribing.

Prescription transmission to pharmacy acceptance: median 3 hours (range: 30 minutes to 72 hours). Delays occur during pharmacy verification, especially for new prescribers or patients in states with additional documentation requirements.

Pharmacy acceptance to shipment: median 3 business days (range: 1 to 7 business days). 503B facilities ship faster (median 2 days). 503A facilities compound to order (median 4 days).

Shipment to delivery: median 2 business days (range: 1 to 5 business days). Overnight shipping available for additional fee.

Overall median timeline: 7 business days from account creation to first dose delivery. 10th percentile (fastest): 3 business days. 90th percentile (slowest): 14 business days.

The most common delay point: patients who start the medical history intake but don't complete it. Median time to completion for patients who pause mid-intake: 4 days.

Cost structure and what's included in monthly pricing

Compounded semaglutide pricing varies by dose, formulation, and pharmacy. As of April 2026, typical monthly costs:

Starting dose (0.25 mg weekly): $199 to $249 per month Low dose (0.5 mg weekly): $249 to $299 per month Medium dose (1.0 mg weekly): $299 to $399 per month High dose (1.7 to 2.4 mg weekly): $399 to $499 per month

What's typically included:

• Medication (multi-dose vial, typically 4 to 8 weeks supply)
• Syringes and needles (sufficient for prescribed duration)
• Alcohol prep pads
• Sharps container (first order only)
• Temperature-controlled shipping
• Provider consultation (initial and follow-up)
• Ongoing clinical support (messaging, dose adjustments)

What's typically NOT included:

• Lab work (if required, typically $50 to $150 for metabolic panel)
• Overnight shipping upgrade ($25 to $50)
• Additional supplies if lost or damaged
• Refills without provider re-evaluation

Insurance coverage: Most insurance plans do not cover compounded semaglutide because it is not FDA-approved. Some FSA and HSA accounts can be used for payment, but this varies by plan administrator.

Discount programs: Some telehealth platforms offer subscription pricing that reduces per-month cost. FormBlends's subscription model reduces cost by 15% for patients who commit to 6-month programs.

Price comparison to FDA-approved products: Brand-name Wegovy costs $1,349 per month without insurance (Novo Nordisk list price, 2026). With insurance coverage, patient copays range from $25 to $500 depending on plan. Compounded semaglutide is typically less expensive than brand-name out-of-pocket cost but more expensive than insured brand-name copays for patients with good coverage.

The FormBlends access model: pattern recognition from 18 months of data

FormBlends has facilitated compounded semaglutide access for patients across 50 states since October 2024. Several consistent patterns have emerged.

Pattern 1: The "insurance rejection" pathway. Approximately 60% of FormBlends patients attempted to obtain FDA-approved semaglutide through insurance first. The median time spent navigating prior authorization, step therapy, and appeals: 6 weeks. After insurance denial, patients turn to compounded options. This population tends to be more informed about GLP-1 therapy and has realistic expectations about side effects and outcomes.

Pattern 2: The "cost-conscious" pathway. Approximately 25% of patients choose compounded semaglutide as first-line because of cost, even when insurance might cover brand-name products. This group includes patients with high-deductible plans where the insured price still exceeds $400 per month, and patients who prefer to keep weight-loss treatment off their insurance record.

Pattern 3: The "shortage-driven" pathway. Approximately 15% of patients come to compounded semaglutide because FDA-approved products are unavailable at their local pharmacy. This pattern peaked during the 2023-2024 shortage but persists in rural areas where pharmacies don't stock Wegovy or Ozempic due to low demand.

Conversion rate from consultation to prescription: 78%. The most common reasons for non-conversion: BMI below threshold without qualifying comorbidity (12%), absolute contraindication discovered during evaluation (6%), patient decision to delay after learning about side effects (4%).

Median time to first dose adjustment: 6 weeks. Most patients start at 0.25 mg weekly and titrate to 0.5 mg at week 5 or 6, following the standard Wegovy titration schedule.

Adherence at 6 months: 64% of patients who start compounded semaglutide are still active on treatment at 6 months. This is slightly lower than the 68% adherence rate reported for FDA-approved semaglutide in real-world studies (Overgaard et al., Diabetes Obesity and Metabolism 2024), likely because compounded patients are fully self-pay and more price-sensitive.

When you should NOT pursue compounded semaglutide

A steelman case against compounded semaglutide access, even if you qualify clinically:

Reason 1: You have good insurance coverage for FDA-approved products. If your insurance covers Wegovy or Ozempic with a copay under $100 per month, the FDA-approved product is the better choice. It has undergone full FDA review, has more extensive safety data, and comes in a pre-filled pen that's easier to use than vial-and-syringe administration.

Reason 2: You have a history of medication non-adherence. Compounded semaglutide requires weekly self-injection, proper refrigeration, and consistent follow-up with a provider. If you frequently miss doses or forget to refill medications, GLP-1 therapy (compounded or otherwise) is unlikely to succeed. The medication only works if you take it consistently.

Reason 3: You're not prepared to modify diet and exercise. Semaglutide is not a monotherapy. Clinical trials showing significant weight loss combined semaglutide with reduced-calorie diet and increased physical activity (Wilding et al., NEJM 2021). Patients who take semaglutide without lifestyle modification lose less weight and are more likely to discontinue due to side effects.

Reason 4: You're using it for "the last 10 pounds." If your BMI is 24 and you want to get to 22 for aesthetic reasons, compounded semaglutide is not appropriate. Providers who prescribe GLP-1 therapy outside FDA criteria are practicing below the standard of care and exposing themselves to liability. More importantly, the risk-benefit ratio doesn't favor medication use in patients without medical obesity.

Reason 5: You can't afford consistent treatment. GLP-1 therapy is not a short-term intervention. Most patients require 12 to 24 months of treatment to achieve and maintain significant weight loss. If you can afford 3 months but not 12, you're likely to regain weight after stopping. The research is clear: weight regain after GLP-1 discontinuation is common, with patients regaining approximately two-thirds of lost weight within 12 months (Wilding et al., Diabetes Obesity and Metabolism 2022).

Reason 6: Your state has restrictive telehealth laws. Some states require an in-person visit before prescribing controlled or high-risk medications via telehealth. While semaglutide is not controlled, some states treat it as high-risk due to the thyroid cancer warning. If you live in a state with restrictive laws and can't access in-person care, compounded semaglutide may not be legally available via telehealth.

A thoughtful clinician might argue that the proliferation of compounded semaglutide access via telehealth platforms has lowered the bar for prescribing, leading to inappropriate use in patients who don't meet criteria or haven't tried first-line interventions. This concern is legitimate. The counter-argument: traditional healthcare has failed to address obesity effectively for decades, and telehealth platforms are filling a gap in access for patients who genuinely qualify but face barriers in the conventional system.

State-by-state restrictions and pharmacy licensing

Compounded semaglutide is legal in all 50 states, but several states impose additional requirements on prescribing or dispensing.

States requiring in-person visit before telehealth prescribing:

• Texas (requires one in-person visit within 12 months for new patients, telehealth allowed for established patients)
• Louisiana (requires in-person visit for initial prescription, telehealth allowed for refills)
• Arkansas (requires in-person visit for Schedule II-IV drugs; semaglutide is not scheduled, so telehealth is allowed, but some providers interpret the law conservatively)

States with additional pharmacy licensing requirements:

• California (requires pharmacies shipping into California to be licensed by California Board of Pharmacy, even if the pharmacy is located out-of-state)
• New York (requires out-of-state pharmacies to register with New York State Board of Pharmacy)
• Florida (requires out-of-state pharmacies to hold Florida permit if shipping more than 10% of total prescription volume to Florida residents)

States with prescriber-patient relationship documentation requirements:

• Texas, Louisiana, Georgia, Ohio, and Tennessee require documentation that a valid prescriber-patient relationship exists before dispensing. This typically means the provider must document the medical evaluation in a format the pharmacy can verify.

States with quantity limits on compounded injectables:

• Illinois (90-day supply maximum per prescription)
• Michigan (90-day supply maximum per prescription)
• Pennsylvania (60-day supply maximum for compounded sterile preparations)

FormBlends's provider network includes clinicians licensed in all 50 states, and our pharmacy partners hold the necessary licenses to ship to all states. Patients in Texas and Louisiana complete a brief video consultation (even if the rest of the evaluation is asynchronous) to satisfy in-person visit requirements.

What to expect in your first shipment

Your first compounded semaglutide shipment typically includes:

Medication vial: A multi-dose vial containing 4 to 8 weeks of medication, depending on your prescribed dose. The vial is glass, sealed with a rubber stopper and aluminum crimp seal. It may be clear or tinted (red/pink if B12 is added).

Syringes: Insulin syringes, typically 0.5 mL or 1.0 mL capacity with 29-gauge or 31-gauge needles. Quantity matches your prescribed duration (one syringe per injection).

Alcohol prep pads: Typically 10 to 20 pads for injection site preparation and vial top cleaning.

Sharps container: A small biohazard sharps container for safe disposal of used syringes. Included in first shipment only.

Instruction sheet: Printed instructions covering injection technique, dose measurement, storage requirements, and emergency contact information.

Prescription label: Affixed to the vial, listing medication name, strength, your name, prescriber name, pharmacy name and contact information, dispensing date, expiration date, and storage instructions.

Insulated shipping box: The medication arrives in an insulated box with gel packs or dry ice to maintain refrigeration during transit. The box may include a temperature indicator showing whether the shipment stayed within safe temperature range.

What you should do immediately upon delivery:

1. Inspect the package for damage or signs of temperature excursion
2. Check the temperature indicator (if included) to confirm cold chain was maintained
3. Inspect the vial for clarity, color (if expected), and absence of particles
4. Verify the prescription label matches your prescription
5. Refrigerate the medication immediately at 36 to 46°F
6. Review the instruction sheet before first injection

If anything looks wrong (damaged packaging, warm medication, cloudy vial, incorrect label), contact the pharmacy before using the medication. Most pharmacies have a 24-hour emergency line for medication quality concerns.

FAQ

How do I get compounded semaglutide without insurance? Complete a medical evaluation with a licensed provider (telehealth or in-person), receive a prescription if you meet clinical criteria (BMI ≥27 with comorbidity or BMI ≥30), and have the prescription filled at a compounding pharmacy. Most compounded semaglutide is cash-pay, with monthly costs ranging from $199 to $499 depending on dose.

Can I get compounded semaglutide online? Yes, through telehealth platforms that connect you with licensed providers. The provider conducts a medical evaluation remotely, writes a prescription if appropriate, and transmits it to a compounding pharmacy that ships the medication to you. You cannot purchase compounded semaglutide without a prescription.

Do I need a prescription for compounded semaglutide? Yes. Semaglutide is a prescription-only medication under federal law. All legitimate compounding pharmacies require a valid prescription from a licensed provider before dispensing. Websites claiming to sell semaglutide without prescription are operating illegally.

How long does it take to get compounded semaglutide? The typical timeline is 5 to 10 business days from initial consultation to delivery. Telehealth consultations are usually completed within 24 to 48 hours. Pharmacy compounding and shipping takes 3 to 7 business days. Expedited options may be available for additional cost.

What's the difference between 503A and 503B compounded semaglutide? 503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions under state oversight. 503B outsourcing facilities are federally registered facilities that can compound in larger batches under FDA oversight. For patients, 503B facilities typically ship faster but may cost slightly more.

Can my regular doctor prescribe compounded semaglutide? Yes, if they're willing. Any licensed physician, nurse practitioner, or physician assistant can prescribe compounded semaglutide. However, many primary care providers are unfamiliar with compounding pharmacies or prefer not to prescribe weight-loss medications. Telehealth platforms specialize in GLP-1 prescribing and may be more accessible.

Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It has not undergone FDA approval and may differ in formulation, concentration, or additives. It is not interchangeable with FDA-approved products.

What if I don't meet the BMI requirements? Providers cannot prescribe semaglutide for weight loss if you don't meet FDA criteria (BMI ≥27 with comorbidity or BMI ≥30). Some providers may prescribe for off-label indications like prediabetes or metabolic syndrome in patients with lower BMI, but this is outside standard practice guidelines.

Can I use my FSA or HSA to pay for compounded semaglutide? Usually yes. Most FSA and HSA administrators allow funds to be used for prescription medications, including compounded prescriptions. Check with your plan administrator to confirm. You'll need a receipt from the pharmacy showing it's a prescription medication.

How do I know if the compounding pharmacy is legitimate? Verify the pharmacy is licensed in your state (check your state pharmacy board website). Confirm they're registered as a 503A or 503B facility (503B facilities are listed on the FDA website). Legitimate pharmacies will provide their license numbers, address, and pharmacist contact information on the prescription label.

What happens if I move to a different state during treatment? You'll need to verify that your provider is licensed in your new state and that the pharmacy can ship to that state. Some telehealth platforms have providers licensed in all 50 states. If your provider isn't licensed in your new state, you'll need to establish care with a new provider.

Can I get compounded semaglutide if I'm already on Ozempic? Switching from FDA-approved to compounded semaglutide (or vice versa) requires provider supervision. The dosing may not be equivalent, and timing of the switch matters to avoid gaps or overlaps in therapy. Discuss with your provider before making any changes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2023.
4. Johnson KL et al. Comparison of telehealth and in-person care for GLP-1 receptor agonist therapy. Journal of Telemedicine and Telecare. 2025.
5. Patel SR et al. Continuity of care and weight-loss medication adherence. Obesity Science & Practice. 2024.
6. FDA Drug Quality Report: Compounded GLP-1 Receptor Agonists. September 2024.
7. Overgaard RV et al. Real-world adherence to semaglutide treatment for weight management. Diabetes Obesity and Metabolism. 2024.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
9. FDA Drug Safety Communication: Semaglutide Prescription Requirements. March 2024.
10. Federation of State Medical Boards Telehealth Report. January 2026.
11. National Institutes of Health Office of Dietary Supplements. Vitamin B12 Fact Sheet. 2023.
12. CDC NHANES B12 Deficiency Data. 2018.
13. United States Code Title 21 Section 353(b)(1): Prescription Drug Requirements. 2024.
14. USP and FDA Joint Quality Survey: Compounded GLP-1 Products. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names are referenced for educational comparison only.